What Happened

The FDA approved Eli Lilly's Jaypirca (pirtobrutinib) as the first noncovalent BTK inhibitor for first-line treatment of CLL/SLL. This approval follows earlier green lights in third-line (2023) and second-line settings, making Jaypirca the fourth BTK inhibitor—after Brukinsa, Calquence, and Imbruvica—cleared for previously untreated patients. The decision is based on the phase 3 Bruin CLL-313 trial, which demonstrated an 80% reduction in the risk of progression or death versus bendamustine plus rituximab (BR). Notably, the label excludes patients with known 17p deletion, consistent with the trial population.

Who Is Affected

This regulatory milestone directly impacts Eli Lilly Oncology, its competitors—BeOne Medicines (Brukinsa), AstraZeneca (Calquence), and AbbVie/Johnson & Johnson (Imbruvica)—and the broader CLL/SLL treatment landscape. It also affects commercial teams selling into oncology: product marketing, market access, real-world evidence, and medical affairs functions will need to update positioning, payer messaging, and competitive response plans. Patients now have a fourth first-line BTK inhibitor option, though NCCN guidelines currently favor saving Jaypirca for relapsed patients who have previously used a covalent BTK inhibitor.

Market Impact

• Jaypirca's first-line label expansion broadens its competitive set, but its noncovalent mechanism allows sequential use after covalent inhibitors—a unique differentiation.
• Q2 sales for Jaypirca reached $192 million (up 56% YoY), while Brukinsa generated $1.2 billion, underscoring Jaypirca's smaller but growing footprint.
• Commercial teams must monitor pricing, reimbursement, and physician adoption patterns as Jaypirca enters first-line discussions despite the NCCN's category 2A recommendation (vs category 1 for post-covalent-BTKi use).

What to Watch

Watch for competitive responses from BeOne, AstraZeneca, AbbVie, and J&J, particularly any label expansions or real-world evidence that challenge Jaypirca's positioning. Also monitor Lilly's ongoing development of a fixed-duration regimen combining Jaypirca with venetoclax and rituximab—the phase 3 Bruin CLL-322 trial showed a 45.3% PFS improvement versus venetoclax plus rituximab in previously treated CLL/SLL. Finally, track payer coverage decisions and NCCN guideline updates as Jaypirca's first-line role evolves.

Related coverage

• TRex Bio and Retension Pharmaceuticals file for IPO; ADARx eyes up to $446M listing
• FDA Approves Eli Lilly's Once-Weekly Basal Insulin Onswik for Type 2 Diabetes
• FDA approves AstraZeneca’s Etcamah for breast cancer
• Foghorn lays off 40% of employees as Lilly cancer collab collapses over poor data